Changes of lens culinaris agglutinin-reactive alpha-fetoprotein (AFP-L3 fraction) after complete radiofrequency ablation for hepatocellular carcinoma
Chikara Ogawa, Masatoshi Kudo(Kindai University), Yasunori Minami, Masayuki Kitano(Wakayama Medical University), Shigenaga Matsui, Emi Ishikawa(Kyowa Chemical Industry (Japan)), Yoichiro Suetomi, Ryosuke Nakaoka, Mikio Shiomi, Nobuhiro Fukuda, Toshihiko Kawasaki(Kindai University), Hobyung Chung(Kindai University)
Cited by 0
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> Study
|Liver International|2015|1.3k